Nuvectis Pharma, Inc. beat EPS estimates 44% of the time across 16 reported quarters (7 beats, 9 misses), averaging -10.3% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-0.25 | $-0.30 | -20.0% | Miss | |
| Q1 FY26 | $-0.30 | $-0.26 | +13.3% | Beat | |
| Q4 FY25 | $-0.26 | $-0.31 | -19.2% | Miss | |
| Q3 FY25 | $-0.24 | $-0.44 | -83.3% | Miss | |
| Q2 FY25 | $-0.25 | $-0.30 | -20.0% | Miss | |
| Q1 FY25 | $-0.30 | $-0.27 | +10.0% | Beat | |
| Q4 FY24 | $-0.28 | $-0.36 | -28.6% | Miss | |
| Q3 FY24 | $-0.26 | $-0.24 | +7.7% | Beat | |
| Q2 FY24 | $-0.26 | $-0.26 | +0.0% | Beat | |
| Q1 FY24 | $-0.40 | $-0.25 | +37.5% | Beat | |
| Q4 FY23 | $-0.40 | $-0.41 | -2.5% | Miss | |
| Q3 FY23 | $-0.38 | $-0.37 | +2.6% | Beat |
Back to NVCT overview · NVCT holders · NVCT KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.